Development of secreted proteins as biotherapeutic agents

Bibliography

• CLARK HF, GURNEY AL, ABAYA E et al.: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. (2003) 13:2265–2270.
   PubMed Web of Science ®Google Scholar
• •A good review on bioinformatic approaches to identify extracellular proteins.
   Google Scholar
• BONKOBARA M, DAS A, TAKAO Jet al.: Identification of novel genes for secreted and membrane-anchored proteins in human keratinocytes. &J. DerinatoL (2003) 148:654–664.
   Google Scholar
• JUNG LL, SCHWARTZ RN: Darbepoetin alfa: a review of its use in patients with cancer. Cancer Piaci (2002) 10:327–330.
   Web of Science ®Google Scholar
• •A good review on application in cancer.
   Google Scholar
• LITTLEWOOD TJ, CELLA D, NORTIER JW: Erythropoietin improves quality of life. Lancet Oncol (2002) 3:459–460.
   PubMed Web of Science ®Google Scholar
• OWENS DR, ZINMAN B, BOLLI GB: Insulins today and beyond. Lancet (2001) 358:739–746.
   PubMed Web of Science ®Google Scholar
• BETHEL MA, FEINGLOS MN: Insulin analogues: new therapies for type 2 diabetes mellitus. Carr. Blab. Rep. (2002) 2:403–408.
   PubMedGoogle Scholar
• •A good overview on recent methods for insulin analogues.
   Google Scholar
• DILLS DG: New aspects of insulin therapy in type 1 and type 2 diabetes. Carr. Blab. Rep. (2001) 1:112–118.
   PubMedGoogle Scholar
• BOLLI GB, OWENS DR: Insulin glargine. Lancet (2000) 356:443–445.
   PubMed Web of Science ®Google Scholar
• ISAACS A, LINDENMANN J: Virus interference: I. The interferon. Proc. R. Soc. (1957) 147:258–267.
   Web of Science ®Google Scholar
• NAGATA S, TAIRA H, HALL A et al.: Synthesis in E. cob of a polypeptide with human leukocyte interferon activity. Nature (1980) 284:316–320.
   Google Scholar
• QUESADA JR, REUBEN J, MANNING JT et al: Alpha interferon for induction of remission in hairy-cell leukemia. N Engl. I Med. (1984) 310:15–18.
   PubMed Web of Science ®Google Scholar
• LINDSAY KL: Treatment of chronic hepatitis C: comparative virologic response rates among the different interferons. .1. Hepatol (1999) 31\(Suppl. 1):232–236.
   Google Scholar
• WEISSMANN C: Recombinant interferon - the 20th anniversary. (2001):3–41.
   Google Scholar
• ZEIN CO, ZEIN NN: Advances in therapy for hepatitis C infection. Microbes Infect. (2002) 4:1237–1246.
   PubMed Web of Science ®Google Scholar
• COLLEN D, LUNEN HR: Basic and clinical aspects of fibrinolysis and thrombolysis. Blood (1991) 78:3114–3124.
   PubMed Web of Science ®Google Scholar
• LIJNEN HR: Elements of the fibrinolytic system. Ann. NY Acad. Sci. (2001) 936:226–236.
   PubMed Web of Science ®Google Scholar
• PENNICA D, HOLMES WE, KOHR WJ et al.: Cloning and expression of human tissue-type plasminogen activator cDNA in E. coil. Nature (1983) 301:214–221.
   PubMed Web of Science ®Google Scholar
• ••Detailed methods on expression in E. coll.
   Google Scholar
• COLLEN D, STASSEN JM, MARAFINO BJ JR et al: Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. PharinacoL Exp. Titer. (1984) 231:146–152.
   PubMed Web of Science ®Google Scholar
• SCHLANDT RC: Reperfusion in acute myocardial infarction. Circulation (1994) 90:2091–2102.
   PubMed Web of Science ®Google Scholar
• SEIFRIED E, TANSWELL P, RIJKEN DC et al: Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Arzneimittelfotschung (1988) 38:418–422.
   PubMed Web of Science ®Google Scholar
• WELTE K, PLATZER M: Colony-stimulating factors: altering the practice of oncology. (2001):89–106.
   Google Scholar
• LIES CHKE GJ, BURGESS AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl. I Med. (1992) 327:28–35.
   PubMed Web of Science ®Google Scholar
• LIESCHKE GJ, GRAIL D, HODGSON G et al: Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood (1994) 84:1737–1746.
   PubMed Web of Science ®Google Scholar
• STANLEY E, LIES CHKE GJ, GRAIL D et al.: Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc. Natl. Acad. Sci. USA (1994) 91:5592–5596.
   PubMed Web of Science ®Google Scholar
• SPIEKERMANN K, ROESLER J, EMMENDOERFFER A et al.: Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Leukemia (1997) 11:466–478.
   PubMed Web of Science ®Google Scholar
• GISSELBRECHT C, PRENTICE HG, BACIGALUPO A et al.: Placebo-controlled Phase III trial of lenograstim in bone- marrow transplantation. Lancet (1994) 343:696–700.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, ROSENFELD CS, ASH R et al.: Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant. (1995) 15:949–954.
   PubMed Web of Science ®Google Scholar
• BOLWELL BJ, GOORMASTIC M, YANSSENS T et al: Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant. Bone Marrow Transplant. (1994) 14:913–918.
   PubMed Web of Science ®Google Scholar
• DELGADO C, FRANCIS GE,FISHER D: The uses and properties of PEG-linked proteins. Grit. Rev Ther. Drug Carrier Syst. (1992) 9:249–304.
   PubMed Web of Science ®Google Scholar
• •A thorough analysis on using PEGylation.
   Google Scholar
• MOLINEUX G: Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat. Rev. (2002) 28(Suppl. A):13–16.
   Google Scholar
• MOLINEUX G: Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anti-Cancer Drugs (2003) 14:259–264.
   PubMed Web of Science ®Google Scholar
• ELLIOTT S, LORENZINI T, ASHER S et al.: Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat. Biotechnol (2003) 21:414–421.
   PubMed Web of Science ®Google Scholar
• •Detailed information on effect of glycosylation technologies.
   Google Scholar
• EGRIE JC, BROWNE JK: Development and characterization of darbepoetin alfa. Oncology (Nuntingt) (2002) 16:13–22.
   PubMed Web of Science ®Google Scholar
• MACDOUGALL IC: An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial. Transplant. (2001) 16 (Suppl. 3):14–21.
   Google Scholar
• DENNIS MS, ZHANG M, MENG YG et al.: Albumin binding as a general strategy for improving the pharmacokinetics of proteins. Biol. Chem. (2002) 277:35035–35043.
   Web of Science ®Google Scholar
• KOLKMAN JA, STEMMER WP: Directedevolution of proteins by exon shuffling. Nat. Biotechnol (2001) 19:423–428.
   PubMed Web of Science ®Google Scholar
• CHEN C, GRZEGORZEWSKI KJ, BARASH S et al.: An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis. (2003) 21:294-301.
   Google Scholar